Results 71 to 80 of about 54,010 (241)

Modulation of irinotecan metabolism by ketoconazole

, 2002
PURPOSE: Irinotecan (CPT-11) is a prodrug of SN-38 and has been registered for the treatment of advanced colorectal cancer. It is converted by the cytochrome P450 3A4 isozyme (CYP3A4) into several inactive metabolites, including 7-ethyl-10-[4-N-(5 ...
Mathijssen, RHJ; id_orcid, Kehrer, D, de Bruijn, Peter, Sparreboom, A, Verweij, Jaap, Mathijssen, RHJ   +5 more
core   +1 more source

Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review

Pharmaceutics
Background/Objectives: Irinotecan is used in monotherapy or combined with other drugs for treating different cancer streams. SN-38, the active metabolite of irinotecan, is 70% inactivated by the uridine diphosphate (UDP) glucuronosyltransferase family 1 ...
Xando Díaz-Villamarín, María Teresa Nieto-Sánchez, María Martínez-Pérez, Paula Novo-González, Emilio Fernández-Varón, Alicia Torres-García, Beatriz González Astorga, Isabel Blancas, José Cabeza-Barrera, Rocío Morón   +9 more
doaj   +1 more source

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance

, 2020
Aims. We here investigated whether the combination of simvastatin and irinotecan could induce the synergistic effect on colon cancer cells with or without resistance to irinotecan. Methods. We investigated cell proliferation assay and assessed cell death
Hyun Joo Jang, Juah Jang, Eun Mi Hong, Hyun Woo Byun, Sea Hyub Kae, Se Woo Park, Jung Eun Choi, Jin Lee, Min Ho Choi, Dong Hee Koh   +9 more
core  

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. [PDF]

, 2016
BACKGROUND Since the precise mechanism for the pathogenesis of systemic lupus erythematosus (SLE) is unknown, no targeted therapies in addition to immunosuppression are available so far.
Keil, Andreas, Andreas Keil, Herrmann, Martin, Martin Herrmann, Sean R. Hall, Schmid, Ralph, Frese, Steffen R., Frese, Steffen, Steffen Frese, Ralph A. Schmid, Meike Körner, Hall, Sean R., Hall, Sean, Körner, Meike, Schmid, Ralph A.   +14 more
core   +1 more source

Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial

International Journal of Cancer, EarlyView.
Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O. Goetze, Salah E. Al‐Batran, Sonja Loges, Melanie Janning   +17 more
wiley   +1 more source

DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity

International Journal of Cancer, EarlyView.
Pre‐treatment DPYD and UGT1A1 genotyping is increasingly used to prevent fluoropyrimidine‐ and irinotecan‐related toxicity, but variant‐specific real‐world effects remain unclear. In an unselected cohort of cancer patients with actionable genotypes, genotype‐driven dosing improved safety while preserving treatment exposure in high‐risk DPYD c.1905+1G>A
Martina Gambron, Elena Peruzzi, Samantha Perfler, Marcella Montico, Riccardo Cecchin, Elena De Mattia, Michele Spina, Camilla Lisanti, Serena Corsetti, Luisa Foltran, Fabio Puglisi, Rossana Roncato, Erika Cecchin   +12 more
wiley   +1 more source

genotype-guided dosing of irinotecan: time to prioritize patient safety

, 2023
Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable
Ron HJ Mathijssen, Emma C Hulshof, Deenen, Maarten J., Jesse J Swen, Hulshof, Emma C., Hans Gelderblom, Anna MJ Thijs, Henk-Jan Guchelaar, Sofía LJ Peeters, Gelderblom, Hans, Maarten J Deenen, Thijs, Anna Mj, Peeters, Sofía Lj, Guchelaar, Henk Jan, Mathijssen, Ron Hj; id_orcid, Swen, Jesse J.   +15 more
core   +1 more source

Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study

International Journal of Cancer, EarlyView.
Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.
Büsra Akay Hacan, Fatma Gizem Sonugür, Müge Öçal, Cansu Babahan, Samira Abgarmi, Ülkü Yalçıntaş Arslan, Mehmet Ali Şendur, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut   +9 more
wiley   +1 more source

The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis

, 2015
OBJECTIVE The treatment of lupus nephritis is still an unmet medical need requiring new therapeutic approaches. Our group found recently that irinotecan, an inhibitor of topoisomerase I (topo I), reversed proteinuria and prolonged survival in mice ...
Keil, Andreas, Schmid, Ralph, Frese, Steffen R., Andreas Keil, Frese-Schaper, Manuela, Steffen Frese, Ralph A. Schmid, Steiner, Selina, Meike Körner, Manuela Frese‐Schaper, Körner, Meike, Selina K. Steiner   +11 more
core   +1 more source

Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice

Frontiers in Pharmacology, 2019
Introduction: Acoustic Cluster Therapy (ACT) comprises coadministration of a formulation containing microbubble-microdroplet clusters (PS101) together with a regular medicinal drug and local ultrasound (US) insonation of the targeted pathological tissue.
Nigel Bush, Andrew Healey, Anant Shah, Gary Box, Vladimir Kirkin, Spiros Kotopoulis, Svein Kvåle, Per Christian Sontum, Jeffrey Bamber   +8 more
doaj   +1 more source